Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: The present disclosure provides a marker for predicting prognosis of liver cancer, a composition or kit for predicting prognosis of liver cancer, preferably, a composition or kit for predicting prognosis of liver cancer for predicting the prognosis according to the stage of liver cancer. The marker, composition or kit, and method of the present disclosure make it possible to effectively predict prognosis of liver cancer, preferably, prognosis of liver cancer according to stage.

Abstract: Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFR?, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

Abstract: The present invention relates to a marker for the prognosis of liver cancer; a composition for estimating the prognosis of liver cancer, which contains a substance for detecting a change in the expression level of the prognostic marker for liver cancer; a kit for estimating the prognosis of liver cancer, which contains the composition for estimating liver cancer prognosis; a method for estimating the prognosis of liver cancer using the marker for liver cancer prognosis; and a method for screening a therapeutic agent for liver cancer using the marker for the prognosis of liver cancer.